September 14, 2017. In order to keep our children safe, it is essential to regulate OFRs collectively as a class unless and until there is scientific evidence that one or more particular OFRs is proven to be safe, and then treat that specific OFR differently.
Read More »On Health Policy
NCHR Testimony at the FDA Advisory Committee Meeting on Codeine in Children’s Prescription Cough Medication
September 11, 2017. There are serious risks and no clear benefits for cough medicine with codeine for children of any age. And while we can’t say for certain whether giving opioids to children has long-term negative effects contributing to opioid abuse by teenagers, that logically makes sense. Why not prevent opioid use in children when we can?
Read More »NCHR Comment on the USPSTF’s Draft Research Plan for Abdominal Aortic Aneurysm Screening
September 6, 2017. We support the efforts of the U.S. Preventive Services Task Force (USPSTF) to carefully draft a research plan to guide the systematic review of available evidence for primary care screening to identify and treat AAA. We have two recommendations that would strengthen the USPSTF draft research plan.
Read More »Letter from NCHR about Dangerous Playgrounds and Athletic Fields to the Mayor and City Council of Washington, DC
August 28 2017: The National Center for Health Research (NCHR) is calling on D.C. leaders to halt the use of artificial turf and rubber playground surfaces. They highlight dangers such as lead exposure, excessive heat, and increased injury risks, emphasizing the need for safer, natural alternatives to protect children’s health.
Read More »NCHR Comment on the USPSTF’s Draft Recommendations for Ovarian Cancer Screening
August 10, 2017. We strongly support the USPSTF’s draft recommendation to maintain the “D” grade for ovarian cancer screening, as well as their broader efforts to improve the health of all Americans by making evidence-based recommendations about clinical preventive services. As more high-quality research becomes available, we encourage the provision of additional recommendations about the benefits and harms of using new screening strategies in asymptomatic women who are not known to be at increased risk for ovarian cancer.
Read More »